Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04496375 | An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application(ADN-CO) | unknown | — | 8,000 | Institut Paoli-CalmettesOTHER | 0 | Aug 3, 2020 | clinicaltrials |
| NCT04478916 | Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients(ONCO-AGING) | unknown | — | 144 | Lorenza ScottiOTHER | 1 |
| Jul 28, 2020 |
| clinicaltrials |
| NCT04477057 | PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT04408079 | A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets | unknown | Phase 1 | 70 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04268108 | L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy | unknown | — | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 11, 2020 | clinicaltrials |
| NCT03544723 | Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. | unknown | Phase 2 | 40 | MultiVir, Inc.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04309968 | Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 186 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04423380 | A Study to Investigate Safety and Tolerability of SH3051 Capsule in Patients With Advanced Solid Tumors | unknown | Phase 1 | 45 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04413227 | A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors | unknown | Phase 1 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 2, 2020 | clinicaltrials |
| NCT03468751 | Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Henlix, IncINDUSTRY | 1 | Jun 1, 2020 | clinicaltrials |
| NCT04169178 | Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status | unknown | Phase 1 | 98 | Henlix, IncINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT04367948 | Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma | unknown | N/A | 200 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04360317 | Safety of the Combination of SH003 and Docetaxel in Patients With Solid Cancer | unknown | Phase 1 | 9 | Kyunghee University Medical CenterOTHER | 0 | Apr 24, 2020 | clinicaltrials |
| NCT03950297 | Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A | unknown | Phase 1 | 24 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02638428 | Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | unknown | Phase 2 | 90 | Samsung Medical CenterOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT04300088 | A Prospective Study of the Relevance of the HLA-G Immune Checkpoint in Cancer Immunotherapy(GEIA) | unknown | — | 281 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Mar 9, 2020 | clinicaltrials |
| NCT03168061 | Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma | unknown | Phase 1 / Phase 2 | 150 | NanoCarrier Co., Ltd.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT04275050 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3303 Tablets | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 19, 2020 | clinicaltrials |
| NCT01566019 | Molecular Screening for Cancer Treatment Optimization(MOSCATO 02) | unknown | N/A | 2,150 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03415659 | Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors | unknown | Phase 1 | 85 | Hubei Biological Medicine Industrial Technology Institute Co., Ltd.OTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03160833 | A Study of HMPL-453 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 33 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT04248348 | Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients(MeTHOS) | unknown | — | 600 | Metaxa HospitalOTHER | 1 | Jan 30, 2020 | clinicaltrials |
| NCT03324841 | POA Prospective Repository | unknown | — | 10,000 | Caris Science, Inc.INDUSTRY | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04228406 | Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 | unknown | Phase 1 | 62 | Fujian Cosunter Pharmaceutical Co. LtdINDUSTRY | 1 | Jan 14, 2020 | clinicaltrials |
| NCT04179656 | The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor | unknown | Phase 2 | 100 | Tianjin Medical University Second HospitalOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT04151186 | A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors | unknown | N/A | 72 | suhaichuanOTHER | 0 | Nov 5, 2019 | clinicaltrials |
| NCT04151329 | A Phase I Clinical Trial of BAT1306 and BAT8001 Injection in Patients With Solid Tumor | unknown | Phase 1 / Phase 2 | 72 | Bio-Thera SolutionsINDUSTRY | 1 | Nov 5, 2019 | clinicaltrials |
| NCT04143789 | Evaluation of AP-002 in Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 61 | Altum Pharmaceuticals INCINDUSTRY | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03897283 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors | unknown | Phase 1 | 22 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT04144855 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3474 Injection | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02963168 | A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies | unknown | Phase 1 | 24 | Athenex, Inc.INDUSTRY | 1 | Oct 17, 2019 | clinicaltrials |
| NCT03879057 | Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors | unknown | Phase 1 | 24 | Peking UniversityOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT03583125 | Study of EOC317 in Chinese Patients With Advanced Solid Tumors | unknown | Phase 1 | 140 | Taizhou EOC Pharma Co., Ltd.INDUSTRY | 1 | Sep 11, 2019 | clinicaltrials |
| NCT04076137 | Targeted T-cell Therapy in Solid Tumors | unknown | Early Phase 1 | 10 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Sep 3, 2019 | clinicaltrials |
| NCT03258099 | Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients | unknown | — | 2,200 | Cui YiminOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03258151 | Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients | unknown | — | 2,200 | Cui YiminOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03991559 | A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03927599 | Advanced Refractory Solid Tumors With TP53 Mutations Register Study | unknown | — | 100 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 20, 2019 | clinicaltrials |
| NCT04049929 | A Phase I Study of YY-20394 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
| NCT03641794 | Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers | unknown | Phase 1 | 56 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Aug 1, 2019 | clinicaltrials |
| NCT02575638 | Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48) | unknown | Phase 1 | 65 | Cao Pharmaceuticals Inc.INDUSTRY | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04001569 | AZD8186 and Paclitaxel in Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 49 | Seoul National University Bundang HospitalOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT03977766 | Feasibility of a Process of Digital Validation of Chemotherapies in a Day Treatment Unit(CPV2-0) | unknown | N/A | 150 | Institut Paoli-CalmettesOTHER | 0 | Jun 6, 2019 | clinicaltrials |
| NCT03975036 | Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody | unknown | Phase 2 / Phase 3 | 100 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03757936 | A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 1 | May 23, 2019 | clinicaltrials |
| NCT01032278 | Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT) | unknown | N/A | 597 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03787953 | A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors | unknown | — | 400 | Chinese PLA General HospitalOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT03940820 | Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03929653 | Personalized Therapy of Molecular Tumor Board Participation With the Guidance of Next Generation Sequencing | unknown | — | 500 | Tianjin Medical University Second HospitalOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT03929965 | Anlotinib in Advanced Solid Tumors With FGFR Alteration | unknown | N/A | 30 | Shanghai Changzheng HospitalOTHER | 1 | Apr 29, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2020source: clinicaltrials